AR105755A1 - Compuestos que participan en unión cooperativa y sus usos - Google Patents
Compuestos que participan en unión cooperativa y sus usosInfo
- Publication number
- AR105755A1 AR105755A1 ARP160100047A ARP160100047A AR105755A1 AR 105755 A1 AR105755 A1 AR 105755A1 AR P160100047 A ARP160100047 A AR P160100047A AR P160100047 A ARP160100047 A AR P160100047A AR 105755 A1 AR105755 A1 AR 105755A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- target
- compounds
- presenter
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101925P | 2015-01-09 | 2015-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105755A1 true AR105755A1 (es) | 2017-11-08 |
Family
ID=56356469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100047A AR105755A1 (es) | 2015-01-09 | 2016-01-08 | Compuestos que participan en unión cooperativa y sus usos |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10039839B2 (https=) |
| EP (3) | EP3757109A1 (https=) |
| JP (5) | JP2018507251A (https=) |
| AR (1) | AR105755A1 (https=) |
| MA (1) | MA41381A (https=) |
| TW (1) | TW201629069A (https=) |
| WO (1) | WO2016112279A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428845B1 (en) | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| TW201629069A (zh) * | 2015-01-09 | 2016-08-16 | 霍普驅動生物科技股份有限公司 | 參與協同結合之化合物及其用途 |
| US10533016B2 (en) | 2015-01-09 | 2020-01-14 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
| WO2017059207A1 (en) | 2015-10-01 | 2017-04-06 | Warp Drive Bio, Inc. | Methods and reagents for analyzing protein-protein interfaces |
| CA3020594A1 (en) | 2016-04-12 | 2017-10-19 | Warp Drive Bio, Inc. | Compositions and methods for the production of compounds |
| KR20240093922A (ko) * | 2017-04-05 | 2024-06-24 | 레볼루션 메디슨즈, 인크. | 단백질-단백질 계면을 분석하기 위한 방법 및 시약 |
| AU2018248417A1 (en) * | 2017-04-05 | 2019-11-14 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
| EA201992476A1 (ru) * | 2017-04-18 | 2020-02-25 | Икс-Чем, Инк. | Способы идентификации соединений |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| CN120699039A (zh) | 2019-11-04 | 2025-09-26 | 锐新医药公司 | Ras抑制剂 |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| AU2022268962A1 (en) | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN116083290B (zh) * | 2022-11-21 | 2024-06-14 | 陕西省微生物研究所 | 一种铅锌和/或抗生素和/或抗性基因污染土壤修复的复合微生物菌剂及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0562853T3 (da) | 1992-03-27 | 1996-07-01 | American Home Prod | 29-Demethoxyrapamycin til fremkaldelse af immunsuppression |
| ES2164713T3 (es) | 1993-09-20 | 2002-03-01 | Univ Leland Stanford Junior | Produccion recombinante de nuevos poliquetidos. |
| IL112873A (en) | 1994-03-08 | 2005-03-20 | Wyeth Corp | Rapamycin-fkbp12 binding proteins, their isolation and their use |
| GB9410142D0 (en) | 1994-05-20 | 1994-07-06 | Univ Warwick | Carbapenems |
| GB9524630D0 (en) * | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| US6902913B2 (en) | 1997-04-30 | 2005-06-07 | Kosan Biosciences, Inc. | Recombinant narbonolide polyketide synthase |
| US6153383A (en) | 1997-12-09 | 2000-11-28 | Verdine; Gregory L. | Synthetic transcriptional modulators and uses thereof |
| ES2347027T3 (es) * | 1998-05-22 | 2010-10-22 | The Board Of Trustees Of The Leland Stanford Junior University | Moleculas bifuncionales y terapias basadas en las mismas. |
| GB9927191D0 (en) | 1999-11-17 | 2000-01-12 | Angeletti P Ist Richerche Bio | Methods and means for regulation of gene expression |
| US20070203168A1 (en) * | 2006-02-28 | 2007-08-30 | Zhao Jonathon Z | Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same |
| WO2010031185A1 (en) | 2008-09-19 | 2010-03-25 | Protox Therapeutics Inc. | Treating cancer stem cells using targeted cargo proteins |
| EP2342335B1 (en) | 2008-09-24 | 2015-09-16 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Novel gene cluster |
| WO2010088573A1 (en) | 2009-01-30 | 2010-08-05 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues for preventing or treating hepatitis c infection |
| JP2012532929A (ja) | 2009-07-13 | 2012-12-20 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 二機能性のステープリングされたポリペプチドおよびそれらの使用 |
| EP2456777A2 (en) | 2009-07-24 | 2012-05-30 | Université Henri Poincaré - Nancy 1 | Stambomycin and derivatives, their production and their use as drugs |
| US20130072439A1 (en) | 2009-09-22 | 2013-03-21 | Huw M. Nash | Peptidomimetic macrocycles |
| US20120208720A1 (en) | 2009-10-22 | 2012-08-16 | Kenji Kashiwagi | Rapid display method in translational synthesis of peptide |
| EP2646440A4 (en) | 2010-11-30 | 2014-06-18 | Univ Johns Hopkins | CYCLIC HYBRID LIBRARIES AND SCREENS FOR THIS |
| US9428845B1 (en) | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| WO2012174489A2 (en) * | 2011-06-15 | 2012-12-20 | The Ohio State University | Small molecule composite surfaces as inhibitors of protein-protein interactions |
| EP2806274A1 (en) | 2013-05-24 | 2014-11-26 | AIT Austrian Institute of Technology GmbH | Lung cancer diagnostic method and means |
| US20170067894A1 (en) | 2014-03-03 | 2017-03-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method and device for detection of pseudomonas aeruginosa |
| TW201629069A (zh) * | 2015-01-09 | 2016-08-16 | 霍普驅動生物科技股份有限公司 | 參與協同結合之化合物及其用途 |
| KR20210116479A (ko) * | 2018-12-21 | 2021-09-27 | 레볼루션 메디슨즈, 인크. | 공동 결합에 참여하는 화합물 및 그의 용도 |
-
2016
- 2016-01-05 TW TW105100137A patent/TW201629069A/zh unknown
- 2016-01-07 MA MA041381A patent/MA41381A/fr unknown
- 2016-01-08 AR ARP160100047A patent/AR105755A1/es unknown
- 2016-01-08 EP EP20176025.3A patent/EP3757109A1/en not_active Withdrawn
- 2016-01-08 WO PCT/US2016/012631 patent/WO2016112279A1/en not_active Ceased
- 2016-01-08 US US14/991,403 patent/US10039839B2/en active Active
- 2016-01-08 EP EP16735470.3A patent/EP3247377A4/en not_active Withdrawn
- 2016-01-08 EP EP24222224.8A patent/EP4545521A3/en active Pending
- 2016-01-08 JP JP2017555427A patent/JP2018507251A/ja active Pending
-
2018
- 2018-07-16 US US16/036,141 patent/US20180318434A1/en not_active Abandoned
-
2019
- 2019-11-25 JP JP2019211918A patent/JP2020063256A/ja active Pending
-
2021
- 2021-06-10 US US17/344,566 patent/US20220143202A1/en not_active Abandoned
-
2022
- 2022-05-06 JP JP2022076767A patent/JP2022093718A/ja active Pending
-
2024
- 2024-08-02 JP JP2024127925A patent/JP2024149655A/ja active Pending
- 2024-09-27 US US18/899,370 patent/US20250121077A1/en active Pending
-
2025
- 2025-11-07 JP JP2025188241A patent/JP2026015411A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4545521A3 (en) | 2025-08-06 |
| EP3757109A1 (en) | 2020-12-30 |
| JP2018507251A (ja) | 2018-03-15 |
| EP3247377A4 (en) | 2018-06-13 |
| JP2026015411A (ja) | 2026-01-29 |
| US20160199506A1 (en) | 2016-07-14 |
| MA41381A (fr) | 2017-11-28 |
| US20180318434A1 (en) | 2018-11-08 |
| TW201629069A (zh) | 2016-08-16 |
| EP4545521A2 (en) | 2025-04-30 |
| JP2020063256A (ja) | 2020-04-23 |
| JP2024149655A (ja) | 2024-10-18 |
| JP2022093718A (ja) | 2022-06-23 |
| WO2016112279A8 (en) | 2016-09-29 |
| US10039839B2 (en) | 2018-08-07 |
| US20250121077A1 (en) | 2025-04-17 |
| EP3247377A1 (en) | 2017-11-29 |
| US20220143202A1 (en) | 2022-05-12 |
| WO2016112279A1 (en) | 2016-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105755A1 (es) | Compuestos que participan en unión cooperativa y sus usos | |
| EP4289950A3 (en) | Macrocyclic compounds that participate in cooperative binding and medical uses thereof | |
| EP4242304A3 (en) | Methods and reagents for analyzing protein-protein interfaces | |
| MX2025014195A (es) | Metodos y reactivos para analizar las interfaces entre proteinas | |
| CO2021017741A2 (es) | Proteínas de fusión flt3l-fc y métodos de uso | |
| BR112019012964A2 (pt) | polipeptídeos multiméricos moduladores de célula t e métodos de uso dos mesmos | |
| BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
| BR112018006237A2 (pt) | proteínas de ligação a pd-1 e métodos de uso das mesmas | |
| WO2020236972A3 (en) | Non-classi engineered crispr-cas polynucleotide targeting system | |
| EA202091420A1 (ru) | Радиоактивное мечение полипептидов | |
| BR112017018941A8 (pt) | Molécula de ligação a cd20, seu uso, composição e método in vitro para direcionar a morte mediada por complemento de uma célula que expressa cd20 | |
| EP4365597A3 (en) | Methods of assaying proteins | |
| GB9911047D0 (en) | Assay method and means | |
| MX392031B (es) | Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2 | |
| CA3033327A1 (en) | Programmable cas9-recombinase fusion proteins and uses thereof | |
| AR101400A1 (es) | Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido | |
| AR108468A1 (es) | POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS | |
| MX2022016192A (es) | Anticuerpos anti-nectina-4 condicionalmente activos. | |
| MX2017009680A (es) | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). | |
| EA201892503A1 (ru) | Модуляция метаболизма липидов для продуцирования белков | |
| EP4438626A3 (en) | New anti-sirpa antibodies and their therapeutic applications | |
| WO2020154714A3 (en) | Systems and methods for modulating crispr activity | |
| EP4001310A3 (en) | Ion channel modulators and uses thereof | |
| EP4306544A3 (en) | Production of heteromultimeric proteins using mammalian cells | |
| MX2021015356A (es) | Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |